GlassScriptPhysician profile
Katelynn Faulk
NPI 1528554508
$6,027.96
in general payments reported to CMS, 2019-2025
29 companies · $825 in 2025
The $825 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $2,027 · 2023: $1,678 · 2024: $822 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.74 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,281.21 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $668.89 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $509.83 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $501.44 | 2021-2025 | Entyvio, Eohilia |
| Celgene Corporation | $301.49 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $296.92 | 2021-2025 | Linzess |
| Daiichi Sankyo INC. | $179.75 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $139.95 | 2022-2023 | Dupixent |
| Qol Medical, LLC | $133.79 | 2022-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $116.28 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $113.18 | 2021-2024 | Ocaliva |
| Braintree Laboratories, INC. | $94.22 | 2022-2023 | Sutab |
| Vivus LLC | $80.43 | 2022-2024 | Qsymia |
| Nestle Healthcare Nutrition INC. | $79.15 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $78.69 | 2022-2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $68.01 | 2021-2022 | |
| Redhill Biopharma INC. | $58.54 | 2022-2023 | Movantik, Talicia, Aemcolo |
| Pfizer INC. | $57.27 | 2022-2023 | |
| Enterra Medical, INC. | $49.80 | 2025 | |
| Aimmune Therapeutics, INC. | $47.45 | 2024 | |
| Phathom Pharmaceuticals, INC. | $32.92 | 2024-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $21.23 | 2025 | Terlivaz |
| Ardelyx, INC. | $20.96 | 2023 | Ibsrela |
| Genzyme Corporation | $18.25 | 2024 | |
| Lilly USA, LLC | $16.97 | 2024 | Omvoh |
| Celltrion USA INC. | $16.70 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $15.90 | 2024 | |
| Medline Industries LP | $15.39 | 2025 | |
| Evoke Pharma, INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelynn Faulk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.